Imiquimod, an immune response modifier, is dependent on the OGF-OGFr signaling pathway
Thursday, July 24, 2008 - 12:28
in Health & Medicine
Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered that the efficacy of imiquimod, a clinically important immune response modifier with potent antiviral and antitumor activity, is dependent on the Opioid Growth Factor (OGF)-OGF receptor (OGFr) axis for its action.